We are live on ! Find out more
BC

Boxer Capital Portfolio holdings

AUM $2.04B
1-Year Est. Return 108.39%
This Fund
S&P 500
This Quarter Est. Return
+60.06%
1 Year Est. Return
+108.39%
3 Year Est. Return
+261.8%
5 Year Est. Return
+1,135.09%
10 Year Est. Return
–
AUM
$883M
AUM Growth
-$53.7M
Cap. Flow
-$141M
Cap. Flow %
-15.97%
Top 10 Hldgs %
73.41%
Holding
37
New
4
Increased
6
Reduced
5
Closed
11

Top Buys

Rank Stock Value
1
SLDB icon
Solid Biosciences
SLDB
+$41.6M
2
SRPT icon
Sarepta Therapeutics
SRPT
+$35.4M
3
ESPR
Esperion Therapeutics
ESPR
+$24M
4
KNSA icon
Kiniksa Pharmaceuticals
KNSA
+$21.2M
5
MDGL icon
Madrigal Pharmaceuticals
MDGL
+$16.7M

Top Sells

Rank Stock Value
1
AVXS
AveXis, Inc. Common Stock
AVXS
+$111M
2
LOXO
Loxo Oncology, Inc
LOXO
+$46.1M
3
GTHX
G1 Therapeutics, Inc. Common Stock
GTHX
+$24.5M
4
BPMC
Blueprint Medicines
BPMC
+$22.9M
5
PTCT icon
PTC Therapeutics
PTCT
+$21.8M

Sector Composition

Rank Sector Weight
1 Healthcare 94.3%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SLDB icon
1
Solid Biosciences
SLDB
$794M
$99.1M 11.22%
185,333
+135,333
+271% +$41.6M
ONC
2
BeOne Medicines Ltd
ONC
$32.8B
$96.8M 10.97%
630,000
– –
MRTX
3
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$77.2M 8.74%
1,565,560
+193,050
+14% +$7.29M
PTCT icon
4
PTC Therapeutics
PTCT
$5.64B
$64.1M 7.26%
1,900,000
-700,000
-27% -$21.8M
ODT
5
DELISTED
Odonate Therapeutics, Inc. Common Stock
ODT
$62.4M 7.07%
2,826,938
– –
WVE icon
6
Wave Life Sciences
WVE
$1.09B
$60.8M 6.89%
1,590,600
+240,600
+18% +$10.4M
ESPR
7
DELISTED
Esperion Therapeutics
ESPR
$53.9M 6.1%
1,375,000
+475,000
+53% +$24M
SRPT icon
8
Sarepta Therapeutics
SRPT
$1.57B
$49.6M 5.61%
+375,000
New +$35.4M
MDCO
9
DELISTED
Medicines Co
MDCO
$45.9M 5.19%
1,250,000
– –
RCKT icon
10
Rocket Pharmaceuticals
RCKT
$340M
$38.6M 4.37%
1,966,051
– –
VKTX icon
11
Viking Therapeutics
VKTX
$3.7B
$35.6M 4.03%
3,750,000
+564,000
+18% +$3.75M
CBAY
12
DELISTED
Cymabay Therapeutics
CBAY
$28.1M 3.18%
2,094,000
-618,986
-23% -$7.75M
MDGL icon
13
Madrigal Pharmaceuticals
MDGL
$10.8B
$26.6M 3.01%
+95,000
New +$16.7M
MGNX icon
14
MacroGenics
MGNX
$235M
$25.7M 2.91%
1,245,000
-955,000
-43% -$21.5M
DBVT
15
DBV Technologies
DBVT
$799M
$20.5M 2.33%
106,500
+4,500
+4% +$1.01M
KNSA icon
16
Kiniksa Pharmaceuticals
KNSA
$5.8B
$20.3M 2.3%
+1,172,700
New +$21.2M
ONCT
17
DELISTED
Oncternal Therapeutics, Inc. Common Stock
ONCT
$20.1M 2.27%
9,357
-2,000
-18% -$5.07M
KURA icon
18
Kura Oncology
KURA
$800M
$15.4M 1.74%
844,789
– –
LITS
19
Lite Strategy Inc
LITS
$32.8M
$11.5M 1.3%
+145,655
New +$8.93M
RETA
20
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
$11.4M 1.29%
325,000
– –
RIGL icon
21
Rigel Pharmaceuticals
RIGL
$681M
$6.57M 0.74%
232,190
-281,810
-55% -$10M
VIRX
22
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
$4.5M 0.51%
60,714
– –
BLPH
23
DELISTED
Bellerophon Therapeutics, Inc.
BLPH
$4.49M 0.51%
123,810
– –
ELDN icon
24
Eledon Pharmaceuticals
ELDN
$261M
$2.27M 0.26%
18,021
– –
RGLS
25
DELISTED
Regulus Therapeutics
RGLS
$1.12M 0.13%
14,148
– –
1
2

Similar funds

FTDI
First Trust Direct Indexing Boston, Massachusetts $1.87B AUM 43.63% 1-Year Est. Return
CIM
Contrarius Investment Management St. Helier, Jersey $1.76B AUM 35.87% 1-Year Est. Return
PRO
Pensioenfonds Rail & OV Utrecht, Netherlands $1.44B AUM 23.73% 1-Year Est. Return
GFS
GYL Financial Synergies West Hartford, Connecticut $1.33B AUM 34.46% 1-Year Est. Return
ECM
Ensemble Capital Management San Francisco, California $1.18B AUM 41.81% 1-Year Est. Return
CIP
Chartwell Investment Partners Berywn, Pennsylvania $2.91B AUM 40.48% 1-Year Est. Return
SEC
Seven Eight Capital New York $1.11B AUM 29.48% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return

Boxer Capital's Q2 2018 Portfolio in Review

As of Q2 2018, Boxer Capital held 37 positions worth $883M, down 5.7% from $937M the previous quarter. Its ten largest holdings account for 73% of the portfolio.

Boxer Capital withdrew a net $141M in Q2 2018, closing 11 positions and reducing 5 holdings. Its most notable exit was AveXis, Inc. Common Stock, an estimated $111M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 94% of assets, down from 95% a quarter earlier.

Against the trend, Boxer Capital opened a new position in Sarepta Therapeutics worth $49.6M.

  • Boxer Capital's largest Q2 2018 buy was Sarepta Therapeutics: 375,000 shares worth $49.6M.
  • Boxer Capital added most to Solid Biosciences in Q2 2018, an estimated $41.6M increase.
  • Boxer Capital's biggest Q2 2018 reduction was PTC Therapeutics, cutting an estimated $21.8M.
  • Boxer Capital fully exited AveXis, Inc. Common Stock in Q2 2018, selling an estimated $111M.
  • Boxer Capital's ten largest holdings make up 73% of its $883M portfolio in Q2 2018.
  • Boxer Capital opened 4 new positions and closed 11 in Q2 2018.
  • Boxer Capital's portfolio value fell 5.7% quarter-over-quarter to $883M.

Based on Boxer Capital's 13F filing for Q2 2018, filed 14 Aug 2018.